Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer

Fig. 5

ICG-001 inhibits aggressive phenotypes and promotes membrane localization of β-catenin in an immunocompetent mouse model of SCC. a Immunofluorescence imaging of β-catenin in HPV-16 E6 and E7-expressing TC-1 tumor cells. ICG-001 induces a cuboidal phenotype in cells dissociated from TC-1 tumors and promotes expression of junctional β-catenin. Representative images are shown for ICG-001 treatment versus DMSO (vehicle) control conditions. b Flow cytometry phenotyping of TC-1 tumor cells. Live, single cells were further gated based on expression of CD45, CD24, CD29, CD133, and E-cadherin (E-cad) as shown (red arrows), and expression profiles of stem cell-like CD24highCD133+E-cad+ (red histograms, black arrows) were compared to CD24CD133E-cad (blue histograms). c Stem cell-like CD24highCD133+E-cad+ population in ICG-001-treated group is greatly diminished. Gating was performed as shown in panel b. d Localization of β-catenin in FACS-sorted CD24highCD133+E-cad+ cells. Treatment of CD24highCD133+E-cad+ cells with ICG-001 resulted in increased membrane distribution of β-catenin compared to vehicle-treated cells

Back to article page